Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 117.93B +74.7% |
| Revenue (ttm) | 54.78B +4.4% |
| Net Income | 4.94B |
| EPS | 4.23 |
| Shares Out | n/a |
| PE Ratio | 23.87 |
| Forward PE | 15.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 214,763 |
| Open | 10,140 |
| Previous Close | 10,210 |
| Day's Range | 10,010 - 10,170 |
| 52-Week Range | 5,305 - 11,350 |
| Beta | 0.85 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 4.1% Decline -- GF Value $20. ...
A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 4.1% Decline -- GF Value $20.26 vs Price $33.24
Teva (TEVA) Advances Vitiligo Treatment into Phase 2b Study
Teva (TEVA) Advances Vitiligo Treatment into Phase 2b Study
Teva Pharmaceutical Industries Transcript: Study result
A phase I-B study of anti-IL-15 in vitiligo showed 42% of patients achieved ≥50% facial improvement and 21% achieved ≥75% at 24 weeks, with high patient satisfaction and favorable safety. The antibody's quarterly dosing and efficacy compare well to oral JAKs, and broader development in related diseases is underway.
Teva Pharmaceutical Industries Press release: Study result
Teva Pharmaceutical Industries issued a press release on July 7, 2026, disclosing material business information to investors.
Teva Pharmaceutical Industries Slides: Study result
Teva Pharmaceutical Industries has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Teva to advance TEV-‘408 into Phase 2b study in vitiligo in Q4
Teva (TEVA) announced plans to advance its TEV-‘408, an investigational anti-interleukin-15 monoclonal antibody, into a Phase 2b study in vitiligo in the fourth quarter of 2026. The decision follows e...
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Eli Lilly and dominance in weight loss and diabetes treatments continues to fuel massive revenue growth. Teva Pharmaceutical Industries offers a value-oriented play as it moves past legal hurdles and ...
Is Teva Pharmaceutical Industries Ltd (TEVA) Overvalued After 3.6% Rally? GF Value Says Overvalued
Is Teva Pharmaceutical Industries Ltd (TEVA) Overvalued After 3.6% Rally? GF Value Says Overvalued
SPDW, SPOT, TEVA, SE: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio Developed World ex-US ETF (Symbol: SPDW) where we have ...
Teva Pharmaceutical Industries Ltd (TEVA) Stock Up 3. ...
Teva Pharmaceutical Industries Ltd (TEVA) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 54/100
Insider Sell: Matthew Shields Sells 9,989 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Insider Sell: Matthew Shields Sells 9,989 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Teva Files NDA With FDA For Ecopipam In Pediatric Tourette Syndrome
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA) has submitted its New Drug Application to the U.S. Food and Drug Administration for Ecopipam for the treatment of pediatric Tourette syndrome.
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?
The company is seeing higher-margin growth, with EPS rising 72% year over year in the first quarter. The company's yearly guidance disappointed the markets.
Teva Pharmaceutical Industries (TEVA) Seeks FDA Approval for Ecopipam in Tourette Syndrome
Teva Pharmaceutical Industries (TEVA) Seeks FDA Approval for Ecopipam in Tourette Syndrome
TEVA Advances Pediatric Tourette Syndrome Treatment with New Drug Application
TEVA Advances Pediatric Tourette Syndrome Treatment with New Drug Application
Teva Pharmaceutical Industries Ltd (TEVA) Shares Fall 3.3% -- GF Value Says Still Overvalued
Teva Pharmaceutical Industries Ltd (TEVA) Shares Fall 3.3% -- GF Value Says Still Overvalued
Teva submits NDA for Ecopipam to FDA
The company states: “Teva (TEVA) Pharmaceutical announced the submission of a New Drug Application to the U.S. Food and Drug Administration for ecopipam, a first-in-class investigational therapy for t...
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug A...
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quar...
Analyst Maintains Buy Rating on Teva (TEVA) Amid Recent Performance Concerns
Analyst Maintains Buy Rating on Teva (TEVA) Amid Recent Performance Concerns
Jefferies continues to like Teva after recent pullback
Noting that Teva (TEVA) has underperformed the last two weeks, Jefferies analyst Dennis Ding explained that a “big part of the weakness is due to macro,” but also says it…
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
Teva has a handful of new biosimilars on the market, with more to come. Those assets will doubtlessly deliver some top-line growth.
Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical
CHICAGO--(BUSINESS WIRE)--Paragon Biosciences today announced the closing of the sale of Emalex Biosciences to Teva Pharmaceutical, reinforcing Paragon's ability to build innovative biotechnology comp...
Teva Acquires Emalex For $700 Mln; Ecopipam NDA Planned In H2 2026
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA) announced the completion of its acquisition of Emalex Biosciences for a consideration of $700 million, with the potential for up to an additio...
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva's acquisition of Emalex Biosciences, strengthening it...